Abstract: SA-PO325
Calcimimetics Adherence and Preference in the Management of Uremic Secondary Hyperparathyroidism (SHPT) in Europe
Session Information
- Hemodialysis and Frequent Dialysis: Potpourri
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Nduka, Chidozie U., Amgen, Uxbridge, United Kingdom
- Louie, Karly S., Amgen, Uxbridge, United Kingdom
- Taylor, Jo, Dorset County Hospital NHS Foundation Trust, Dorchester, Dorset, United Kingdom
- Hall, Matt, Nottingham University Hospitals NHS Trust, Nottingham, Nottingham, United Kingdom
- Aucella, Filippo, Fondazione IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy
- Urena Torres, Pablo A., AURA Paris-Nord, Saint-Ouen, France
- Labriola, Laura, Department of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
- Evenepoel, Pieter, Department of Immunology and Microbiology, Division of Nephrology, University Hospitals Leuven, Leuven, Belgium
- Ma, Junjie, Amgen, Thousand Oaks, California, United States
- Saleem, Najma, Amgen, Thousand Oaks, California, United States
- Pisoni, Ronald L., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
- Fouqueray, Bruno L., Amgen GmbH, Rotkreuz, Switzerland
- Horne, Robert, University College London School of Pharmacy, London, London, United Kingdom
Background
Oral cinacalcet (CIN) and intravenous etelcalcetide (ETEL) are approved for treating hemodialysis (HD) patients with SHPT. Data on patient-reported outcomes and calcimimetic preference from nephrologists/nurses’ perspectives are provided in this cross-sectional study.
Methods
Patient questionnaires assessed CIN adherence (Medication Adherence Report Scale [MARS]), calcimimetic perceptions [Beliefs about Medicines Questionnaire (BMQ) and Treatment Intrusiveness Scale (TIS)] and gastrointestinal (GI) symptom experience in the month before enrolment. Nephrologists/nurse questionnaires assessed calcimimetic preference (CIN vs ETEL) based on effectiveness, side effects, patient burden and quality of life (QoL).
Results
414 patients (204 CIN & 210 ETEL) responded to the surveys. Patient characteristics were similar between CIN vs ETEL: mean age 65 vs 64yrs; men 57% vs 61%; mean no. of medications 9 vs 8. CIN adherence was high (mean MARS 4.8), and 78% of patients reported using all CIN prescribed in the month before enrolment. There were no significant differences in perceptions of Calcimimetic Necessity (mean BMQ-Necessity CIN vs ETEL = 3.5±0.7 vs 3.6±0.5, p=0.49), Calcimimetic Concerns (mean BMQ-Concerns CIN vs ETEL = 2.3±0.6 vs 2.3±0.9, p=0.17), or treatment intrusiveness (mean TIS CIN vs ETEL= 1.6±0.7 vs 1.8±0.9). ETEL and CIN patients attributed GI symptoms to calcimimetic use at similar rates: nausea (ETEL 23%; CIN 21%); vomiting (ETEL 26%; CIN 24%) and Diarrhea (ETEL 21%; CIN 21%). Nephrologists (n=111) and nurses (n=113) preferred ETEL for patient adherence (Nephrologist 89%; Nurses 78%); reducing patient burden (Nephrologist 87%; Nurses 86%); minimizing side effects (Nephrologist 78%; Nurses 66%); improving QoL (Nephrologist 72%; Nurses 75%); and effectiveness (Nephrologist 60%; Nurses 74%).
Conclusion
Nephrologists/nurses preferred ETEL for encouraging patient adherence, reducing patient burden, minimizing side effects, improving QoL, and effectiveness. High levels of patient engagement were observed for ETEL and CIN.
Funding
- Commercial Support –